Coming from an AI assistant? The figures in most GLP-1 roundups did not survive checking. See which did. The corrected list → Or read the casebook
GLP-1 Tirzepatide Rank
Comparison matrix
CapturedNexLife$110semaglutide · captured 2026-08-03Trimi$125tirzepatide · captured 2026-07-27Fifty 410$133tirzepatide · captured 2026-07-27NexLife$147tirzepatide · captured 2026-08-03Mochi Health$178semaglutide · captured 2026-08-03Mochi Health$278tirzepatide · captured 2026-08-03LillyDirect$299tirzepatide · captured 2026-07-27CapturedNexLife$110semaglutide · captured 2026-08-03Trimi$125tirzepatide · captured 2026-07-27Fifty 410$133tirzepatide · captured 2026-07-27NexLife$147tirzepatide · captured 2026-08-03Mochi Health$178semaglutide · captured 2026-08-03Mochi Health$278tirzepatide · captured 2026-08-03LillyDirect$299tirzepatide · captured 2026-07-27
Prices 35 verified of 82 Rubric v1.0-draft Captured today 26 Evidence records 105 verified Corrections open log

Analysis

What Tirzepatide Actually Costs at a Maintenance Dose: Five Ladders, Compared

Five providers publish what happens when the dose rises, and every one of them charges more. The steepest published ladder runs $399 to $524, a 31% increase from starter

Direct answer

Five providers publish what happens when the dose rises, and every one of them charges more. The steepest published ladder runs $399 to $524, a 31% increase from starter to maintenance. One programme we captured is flat at $186 across the full range. Ranked on the advertised figure, the flat programme looks mid-table; ranked on the maintenance figure it is the cheapest.

Answer last reviewed: 2026-08-03

What does each published ladder actually do?

The advertised price is almost always the starting dose. Labelling directs increases every four weeks to a maintenance dose of 10 or 15 mg over roughly 20 to 24 weeks, and states 2.5 mg is treatment initiation and is not approved as a maintenance dosage. So the figure most comparison tables rank on is a figure that stops applying in month two.

Every published ladder we can find, starter against maintenance
ProgrammeAdvertised At maintenanceChange Evidence
Flat, 12-month$186 $1860% Captured at source
Flat, month-to-month$215$215 0%Captured at source
Medication plus membership$199$278 +40%Captured at source
Intro month then ongoing$199$299 +50%Reported, provider-published
Intro month then ongoing (2)$349$449 +29%Reported
Dose-tiered$399$449 +13%Reported
Dose-tiered, steepest$399 $524+31%Reported
Brand vials, by dose$299$449 +50%Captured at source

Reported rows come from a competitor's published comparison, which attributes each figure to a third-party review. We record them as reported rather than captured because we have not read them on the provider's own page. Not one published ladder goes down.

The finding

Every provider that publishes a dose ladder charges more at the top of it. The steepest runs +31% from starter to maintenance; the brand's own vial channel runs +50%.

Ranked on the advertised figure, a flat $186 programme sits mid-table behind three cheaper-looking headlines. Ranked on the maintenance figure — the one you actually pay from about month five — it is the cheapest on this page by a margin of $92 to $338 a month.

What twelve months costs: flat against dose-tieredFollowing the label's titration schedule, 2.5 mg to a maintenance dose
$0$1,292$2,585$3,878$5,1711357911Flat, captured · $2,232Flat month-to-month, captured · $2,580Dose-tiered, typical · $2,568Brand Zepbound, captured · $4,788CUMULATIVEMONTH OF TREATMENT
Show this figure as a table
What twelve months costs: flat against dose-tiered: the same data as a tableFollowing the label's titration schedule, 2.5 mg to a maintenance dose
What twelve months costs: flat against dose-tiered: the same data as a table
ProgrammeTwelve-month totalEffective monthly
Flat, captured$2,232$186 average
Flat month-to-month, captured$2,580$215 average
Dose-tiered, typical$2,568$214 average
Brand Zepbound, captured$4,788$399 average
The dose-tiered line uses a typical published escalation pattern; the flat and brand lines are figures we captured at source. A programme advertising $129 finishes the year above one advertising $186. That crossover is the argument this whole site is built on. How we record price structure.

What does that do to a year?

Twelve months, following the label's titration schedule
ProgrammeAdvertised Twelve monthsAgainst the flat plan
Flat, 12-month$186 $2,232
Medication plus membership$199$3,336 +$1,104
Intro then $299 ongoing$199~$3,488 +$1,256
Intro then $449 ongoing$349~$5,288 +$3,056
Dose-tiered to $524$399~$5,900 +$3,668

The programme advertising $13 less than the flat plan costs $1,104 more over the year. The one advertising $213 more costs $3,668 more.

Which structures are honest about it?

This is worth separating from the arithmetic, because the two are not the same thing.

  • A flat rate stated on the provider's own page is the clearest structure: the advertised figure is the maintenance figure.
  • “$199 first month, then $299 all doses” is an intro rate, and a provider printing both numbers in the same sentence has disclosed it properly. The ongoing figure is the one to compare.
  • A published dose ladder — $399, then $499, then $524 — is also honest disclosure. It is more expensive and more transparent than a single teaser figure.
  • A medication price quoted without a mandatory membership is the structure that misleads most, because both numbers are accurate and only one is what you pay.

We rank on the maintenance figure. We do not treat disclosure as a penalty, and a provider that publishes its ladder is doing something the ones with a single unexplained headline are not.

Every tirzepatide protocol we captured at source, 29 July 2026
ProtocolMonthly 3-month6-month 12-month12-month total
Regular injectable$215$195 $190$186$2,232
Microdose$189$159 $150$147$1,764
Sublingual ODT$229$219 $205$199$2,388

Flat at every covered dose within each protocol, read on the provider’s own plan pages. One published plan total does not reconcile against its own monthly rate and we say so — COR-012.

What should I ask?

  1. What will I pay per month at 10 mg, on the plan I would sign? One number means flat. A range means a ladder, and the top of the range is your real cost.
  2. Is that in writing? A landing page can change tomorrow; an email cannot.
  3. Is anything billed separately? Membership, consultation, labs, shipping, dose-increase surcharges.
  4. Is the first month a promotional rate? If so, what is the ongoing figure?

How does every provider score on the six tests?

Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.

Every provider against the six testsComputed from the dataset on 2026-08-03 · 30 providers evaluated
Every provider against the six tests
ProviderCaptured at sourcePublishes a maintenance-dose priceOne published structureNames its fulfilling pharmacyAnswered all four disclosure questionsNo figure we had to withdrawScore
Mochi HealthYesYesYesYesYes5 of 6
NexLifeYesYesYesYesYes5 of 6
Fifty 410YesYesYes3 of 6
LillyDirectYesYesYes3 of 6
TrimiYesYesYes3 of 6
CalibrateYesYes2 of 6
Enhance.MDYesYes2 of 6
Form HealthYesYes2 of 6
Each test comes from a case in our casebook, where a published figure failed a check. The table is generated from the records, not written.
The result, as of 2026-08-03

No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.

That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.

Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.

Medical noteCompounded preparations are not FDA-approved finished products and no trial figure transfers to them. Nothing here is a dosing instruction: any schedule described comes from approved labelling, and your prescriber sets your regimen.
Tirzepatide dosing, as the FDA label sets it outZepbound US Prescribing Information
Tirzepatide dosing, as the FDA label sets it out
StepWhat the label saysStatus
Starting dosage2.5 mg once weekly for 4 weeksInitiation only — not approved as a maintenance dosage Verified
First increaseTo 5 mg once weekly after 4 weeksRecommended maintenance dosage Verified
Further increasesIn 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and responseA minimum interval, not a fixed calendar Verified
7.5 mg and 12.5 mgAvailable strengths used during titrationTitration steps, not recommended maintenance dosages Verified
10 mgOnce weeklyRecommended maintenance dosage Verified
15 mgOnce weeklyRecommended maintenance dosage and the maximum Verified
Above 15 mgNo approved dosage existsVerified Verified
Escalation is driven by tolerability and response, not by a calendar. There are three recommended maintenance dosages, and the right one is a clinical decision.
Why 'cheapest' needs a definition attached
Why 'cheapest' needs a definition attached
Program typeWhat it coversComparable with
Starter programIntroductory period, often lower dosesOther starter programs only
Ongoing programStandard continuing supplyOther ongoing programs only
Maintenance programPost-titration supply, often a fixed doseOther maintenance programs only
Prepaid termSeveral months paid upfrontMonthly plans only after conversion
Month-to-monthCancellable each cycleOther month-to-month plans only
Microdose programSub-therapeutic dosing outside trial evidenceOther microdose programs only
Comparing across rows produces a lower headline number and a meaningless one. We never do it, and neither should a provider quoting you a price.

Frequently asked questions

Does compounded tirzepatide cost more at higher doses?

On every published ladder we can find, yes. The steepest runs from $399 at the starter dose to $524 at 15 mg, a 31% increase. One programme we captured is flat at $186 across the full range.

What is the cheapest tirzepatide at a maintenance dose?

The lowest maintenance figure we have read at source is $186 a month flat, $2,232 over twelve months. Programmes advertising less than that cost between $1,104 and $3,668 more over a year.

Why do comparison tables rank on the starter price?

Because it is the advertised figure. Labelling calls the starting dose treatment initiation rather than a maintenance dosage, so it applies for roughly one month of an indefinite treatment.

Is a published dose ladder a bad sign?

No. A provider printing $399, $499 and $524 has disclosed its structure properly. It is more expensive and more transparent than a single unexplained headline figure.

Cite this pageCC BY 4.0

GLP-1 Tirzepatide Rank. “What Tirzepatide Actually Costs at a Maintenance Dose: Five Ladders, Compared.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/tirzepatide-price-escalation-2026/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error

Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.

Comparing 0 of 4